Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

publication in Clinical Cancer Research highlighting bavituximab's ability to target tumor blood vessels with excellent specificity, and the acceptance last week of an abstract discussing patient data from the Cotara dosimetry trial for presentation at the 2008 ASCO Annual Meeting. We anticipate additional high profile scientific publications and presentations in the coming months while we continue making good progress in advancing our trio of Phase II bavituximab cancer trials, the two ongoing Cotara clinical trials and the trial of bavituximab in HCV patients co-infected with HIV. We look forward to a steady flow of news from these multiple activities in the coming months."

Recent Highlights

Bavituximab Anti-Cancer Program: The company launched the Phase II cancer clinical program for bavituximab during the quarter and achieved a number of other clinical and preclinical advancements.
-- Initiated patient dosing in a Phase II combination therapy trial of

bavituximab and docetaxel in patients with advanced breast cancer

within 14 days of study initiation.

-- Received regulatory approval to begin two additional Phase II

bavituximab combination therapy trials -- one in combination with

carboplatin and paclitaxel in patients with advanced breast cancer and

another in combination with carboplatin plus paclitaxel in patients

with non-small cell lung cancer (NSCLC). Both trials are preparing to

begin enrolling patients shortly.

-- A bavituximab cancer investigator presented data at a leading

scientific meeting on anti-angiogenic agents -- the 10th Annual

International Symposium on Anti-Angiogenic Agents (Angio 2008) --

highlighting the positive clinical experience to date with

bavituximab.

-- A preclinical study published in Clinical Cancer Research confirmed

bavituximab's ability to target tumor blood ves
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW PROVIDENCE, N.J. , Sept. 2, ... a corporate sponsor for MassBio,s 20th Annual Golf Classic, ... MassBioEd Foundation. The event will be held on September ... Plymouth, Massachusetts . The ... Massachusetts through educational programs, workforce development, ...
(Date:9/2/2014)... Press attending the Project LIBERTY Grand Opening have ... people and events in Emmetsburg on Sept. 3. The ... day. Additionally, we will do our best to help ... well as representatives from the local community. Any advance ... remember to RSVP to Matt Merritt (matt.merritt@poetdsm.com) to receive ...
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... orders consist of three large odour control systems for waste ... "These orders are consistent with the market resurgence in ... , President and CEO. "After a difficult period of restraint ... beginning to see sales growth. Our lower cost structure, technology ...
Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
...  Aug. 23, 2011 Reliv International , Inc. ... Science Center today announced a new joint research and ... the latest soy and plant biotechnology research. ... some of the nation,s leading biotech researchers to develop ...
... MedNet Solutions, a global life sciences technology solutions company ... that MedNet has once again been recognized by Inc. ... in the United States.  MedNet is greatly honored to be ... since, as noted by Inc . magazine, "this prestigious ...
... YORK, Aug. 23, 2011 Reportlinker.com ... report is available in its catalogue: ... Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & ... (2010-2015) http://www.reportlinker.com/p0595074/Biochips-Market-DNA-Microarrays-Lab-on-Chip-Protein-Microarrays-Tissue--Cell-Arrays-Trends--Global-Forecast-2010-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics ...
Cached Biology Technology:New Partnership Bolsters Reliv's Access to Plant Biotech Research 2New Partnership Bolsters Reliv's Access to Plant Biotech Research 3MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row 2Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 2Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 3Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 4Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 5Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 6Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 7Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 8Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 9Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 10Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 11Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 12Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 13
(Date:9/2/2014)... published in the September issue of The ... novel strategy to diagnose the leading cause of ... damage has occurred. This advance involves quantifying the ... endothelium of retinal vessels. Using new probes developed ... early molecular development of diabetic retinopathy. , "My ...
(Date:9/2/2014)... perching birds, that migrate by night tend to fly ... reach their destinations. This seasonal difference in flight speed ... migratory flights, says researcher Cecilia Nilsson of Lund University ... Sociobiology . , Nilsson, in a group led ... measure over three years the speed by which birds ...
(Date:9/2/2014)... A study published in the September 2014 issue ... of Child and Adolescent Psychiatry found that ... had an increased risk of developing diabetes if ... from the nationwide Danish registers, a group of ... Aalborg University Hospital, Denmark, studied 48,299children and adolescents ...
Breaking Biology News(10 mins):Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2Migrating birds sprint in spring, but take things easy in autumn 2Risk of diabetes in children and adolescents exposed to antipsychotics 2
... A new study led by York University researchers finds ... marked decrease in performance as a result of their blood ... of Pediatrics, reports that participants, athletic prowess was sapped by ... abilities also declined as a result. "Physical activity ...
... that optical microscopy can,t be used to "see" something ... is wont, clever science has once again overturned conventional ... of the Lawrence Berkeley National Laboratory (Berkeley Lab) Steven ... the use of optical microscopy to ,image objects or ...
... Prostate cancer is the second leading cause of ... cases diagnosed in the US in 2009 (Jemal 2009). ... risk factors for inflammation and prostate diseases including benign ... Sanjay Gupta, MS, PhD, Carter Kissell associate professor & ...
Cached Biology News:Diabetes shouldn't deter young athletes: York U study 2Diabetes shouldn't deter young athletes: York U study 3Correcting a trick of the light brings molecules into view 2Correcting a trick of the light brings molecules into view 3Correcting a trick of the light brings molecules into view 4Mechanism for link between high fat diet and risk of prostate cancer and disorders unveiled 2
UGT1A6 (D-20)...
... the Lone Wolf valve has the highest ... valve available on the market. This VSO ... performance, and ensures maximum accuracy., Achieves ... control and patient comfort. , Maintains ideal ...
Normal Hamster Serum...
...
Biology Products: